Market revenue in 2023 | USD 22.0 million |
Market revenue in 2030 | USD 40.2 million |
Growth rate | 9% (CAGR from 2023 to 2030) |
Largest segment | Chronic periodontal disease |
Fastest growing segment | Chronic Periodontal Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gingivitis, Chronic Periodontal Disease, Aggressive Periodontal Disease, Other Types |
Key market players worldwide | Pfizer Inc, Lupin, Teva Pharmaceutical Industries Ltd ADR, Sun Pharmaceutical Industries, Tokyo Chemical Industry, Bausch Health Companies Inc, Melinta Therapeutics, Cipla Ltd DR, Chartwell Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to periodontal therapeutics market will help companies and investors design strategic landscapes.
Chronic periodontal disease was the largest segment with a revenue share of 34.55% in 2023. Horizon Databook has segmented the Australia periodontal therapeutics market based on gingivitis, chronic periodontal disease, aggressive periodontal disease, other types covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia periodontal therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia periodontal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account